SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401JK is currently trending with strong community enthusiasm, driven by the launch of staking features that reinforce its "pure belief asset" narrative. Members are actively discussing the project as a revolutionary alternative to traditional retirement plans, symbolizing a movement to empower retail investors. This highly engaged community, often comparing itself to past market movements, emphasizes conviction and the goal of early financial freedom.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is currently experiencing heightened community discussion, driven by strong bullish sentiment and predictions for significant long-term growth. Investors are actively debating its enduring role as "digital silver" within the crypto ecosystem, with many anticipating substantial future gains based on historical market cycles.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending amidst an intense community debate, largely driven by persistent rumors of major partnerships with Mastercard and Walmart that could significantly expand Flexa's real-world crypto payment utility. Despite widespread frustration over its past performance and perceived market manipulation, a dedicated investor base maintains that AMP's existing merchant adoption and underlying technology position it as severely undervalued, especially with impending regulatory clarity from the "Clarity Act." This sentiment reflects a critical balance between immediate market skepticism and long-term conviction in its payment infrastructure.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is experiencing high trading volume following news of a strategic manufacturing partnership with Syrma Johari, aimed at scaling production of its fingerprint drug screening reader for anticipated U.S. market entry. This has sparked intense community discussion, with many anticipating significant gains and potential for a short squeeze given the stock's low float, while others express caution regarding a recent offering and potential dilution.

Piggy Bank Token

PIGGY CRYPTO is trending due to its unique real-world utility in Korea's phone charging market, employing a "Charge-to-Earn" model, alongside a recent "A-grade" CertiK security audit. The community is buzzing with bullish sentiment, highlighting strong developer efforts, impactful AMAs, and strategic community collaborations, including notable involvement from a former SafeMoon figure. This has fueled discussions around its growth potential and unique reflection-based tokenomics.

Fidelity Wise Origin Bitcoin Fund - Fidelity Wise Origin Bitcoin Fund Beneficial Interest

Fidelity Wise Origin Bitcoin Fund

Fidelity Wise Origin Bitcoin Fund (FBTC) is experiencing varied sentiment as recent ETF outflows spark community debate over Bitcoin's immediate direction. While some investors are actively adding to long-term positions, especially within retirement accounts, others point to volatility and market dynamics, questioning whether current price movements indicate consolidation or further pressure. This ongoing discussion highlights a split between confidence in institutional adoption and concerns about market manipulation.

Breaking Bread is a pioneer in Solana meme token designed around a simple and transparent rewards system. With 0% tax on trades, every holder benefits directly from activity without hidden costs or penalties. The token automatically redistributes 100% of creator rewards from Pump.fun back to the community, ensuring fair participation for all holders. The project emphasizes consistency, trust, and community engagement, framing daily “breaking of bread” rewards as both a symbolic ritual and a practical way to sustain value for those who participate.

Breaking Bread

BRBR (Breaking Bread) is captivating the crypto community as a pioneering Solana token offering passive $SOL rewards to holders with zero transaction taxes. Discussions revolve around its innovative 'first of its kind' model, strong community commitment, and consistent chart performance, driving enthusiasm for its long-term potential.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending sharply higher following pivotal FDA updates, notably the priority review acceptance for AXS-05 in Alzheimer's disease agitation and positive feedback supporting a submission for AXS-12 in narcolepsy. This has ignited strong bullish sentiment and a surge in trading activity, with the community enthusiastically discussing the company's expanding pipeline and its potential in central nervous system therapeutics.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics (CVKD) is trending due to recent strategic moves, including pipeline expansion through acquisitions and manufacturing advancements for its lead anticoagulant candidate, Tecarfarin. The market is weighing the potential of these developments, including analyst-assigned price targets and FDA designations, against community concerns about cash burn, dilution, and the company's ability to fund pivotal Phase 3 trials. This creates a polarized discussion, highlighting the high-stakes nature of micro-cap biopharma investments.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

The iShares Bitcoin ETF, IBIT, is a focal point of intense discussion, driven by a pending Bank of Japan rate decision that could influence Bitcoin's short-term price action, alongside a recent return of positive ETF inflows. Community sentiment is sharply divided between those anticipating a prolonged 'crypto winter' based on historical cycles and others highlighting sustained institutional accumulation and evolving market dynamics as key factors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MoonLake Immunotherapeutics shares crashed nearly 90% to record its worst session ever on Monday, as analysts downgraded the stock after the company announced late-stage trial results of its lead drug, sonelokimab, for the treatment of moderate-to-severe hidradenitis suppurativa (HS).By the end of the session, the stock had dropped to $6.25, marking its lowest levels in over three years, before gaining approximately 4.7% in after-hours trading.BTIG downgraded MoonLake to 'Neutral' from 'Buy' and removed the stock from its list of top picks for the second half of the year, saying sonelokimab failed to show differentiation in the Phase 3 VELA-1 and VELA-2 trials. The analyst noted that the placebo-adjusted HiSCR75 results were “well into our worst case scenario” and did not demonstrate a clear efficacy advantage over Bimzelx.Jefferies analyst Clara Dong also downgraded the stock to 'Hold' from 'Buy' and reduced the price target to $8 from $65, citing a smaller commercial opportunity, a lower likelihood of approval despite the drug’s potential path forward, and lesser M&amp;A value.Wolfe Research double-downgraded MoonLake to 'Underperform' from 'Outperform' with a steep price target cut to $2 from $76, saying that even if sonelokimab eventually finds a path forward in HS, realizing stock value “will take too long and will be too tough.”&nbsp;The brokerage firm called the outcome a “surprising MoonLake fiasco,” comparing it to Acelyrin’s collapse after its own HS trial failure, noting that Acelyrin’s stock never rebounded despite later-stage programs in PsA and TED.Leerink Partners highlighted Oruka Therapeutics as a likely beneficiary, noting that its drug, ORKA-002, with a mechanism similar to Bimzelx, could gain traction following MoonLake’s results.&nbsp;On Stocktwits, retail sentiment for MoonLake was ‘extremely bullish’ amid a 4,650% surge in 24-hour message volume.One user expressed confidence in MoonLake’s leadership and long-term outlook, stating that the company has a strong management team and a promising future, with potential for eventual FDA approval.<stembedurl>https://stocktwits.com/HitNRun79/message/630422460</stembedurl>Another user noted that the trial results, while not ideal, still showed meaningful efficacy. They suggested that the sharp decline in the stock was driven more by fear and short-seller activity than by fundamentals, and added that they had taken a position in the stock following the selloff.<stembedurl>https://stocktwits.com/freshstart2021/message/630421221</stembedurl><a href="https://stocktwits.com/symbol/MLTX">MoonLake’s stock</a> has declined 88.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades

Wolfe Research compared MoonLake’s setback to Acelyrin’s HS trial failure, noting that Acelyrin’s stock never rebounded despite later progress in other programs.

Equity

Candel Therapeutics Inc. (13% jump in followers)Candel Therapeutics Inc. shares gained momentum as Wall Street analysts&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">highlighted</a> the potential of its lead cancer drug candidate, CAN-2409. Canaccord expects continued clinical success in prostate, pancreatic, and non-small cell lung cancer, noting a significant increase in median overall survival in testing so far. Citi’s modeling suggests CAN-2409 could extend survival in localized prostate cancer by as much as eight to nine years over radiotherapy alone.&nbsp;The stock is up over 35% year-to-date.Acelyrin Inc. (12% jump in followers)Acelyrin confirmed that Concentra Biosciences, controlled by Tang Capital Partners, submitted an unsolicited offer to acquire all outstanding shares of Acelyrin for $3.00 per share in cash, plus a contingent value right tied to future licensing or asset sales.Earlier in the month, Acelyrin announced a merger agreement with Alumis in an all-stock transaction expected to close in the second quarter of 2025, pending shareholder approval.&nbsp;Acelyrin stock is down over 18% year-to-date.Solid Biosciences Inc. (11% jump in followers)Solid Biosciences shares surged after early-stage data from its gene therapy candidate SGT-003 for Duchenne muscular dystrophy&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sldb-stock-soars-on-dmd-trial-data/ch5rNeJRvt">showed</a> promising results.&nbsp;Following the data release, Chardan raised its price target on the stock and increased the therapy’s probability of success to 48%, citing strong early efficacy signals and manageable safety risks.Solid Biosciences stock is up 43% year-to-date.Estrella Immunopharma Inc. (11% jump in followers)Estrella Immunopharma received a bullish initiation from D. Boral Capital, which started coverage with a ‘Buy’ rating and a $16 price target. The firm sees Estrella as a potential major player in immuno-oncology, with its EB103 therapy using ARTEMIS T-cell engineering technology to target solid tumors.&nbsp;The company also completed the first dose cohort in its Phase I/II trial, receiving approval from the Data and Safety Monitoring Board to proceed to the second dose level.&nbsp;Estrella stock is up over 22% year-to-date.Aditxt Inc. (10% jump in followers)Aditxt announced that its subsidiary, Pearsanta, has engaged Dominari Securities as the lead underwriter for its planned initial public offering. The IPO aims to support Pearsanta’s U.S. and international commercial launch of its Mitomic Technology platform for early cancer detection.&nbsp;Pearsanta is developing a non-invasive blood test to detect cancer at earlier stages by leveraging mitochondrial DNA deletions as biomarkers. IPO proceeds will fund the U.S. launch of its Laboratory Developed Tests (LDTs) and drive global commercialization through distribution partnerships and regulatory approvals.&nbsp;Aditxt stock is down over 53% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

SLRN
Acelyrin Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLRN News

SLRNAcelyrin Inc